Menu Search
Funds

Fidelity Advisor Biotechnology Fund - Class I

FBTIX

Fidelity Advisor Biotechnology Fund - Class I

Actions
  • Price (USD)32.86
  • Today's Change0.19 / 0.58%
  • 1 Year change+32.77%
Data delayed at least 15 minutes, as of Nov 20 2024.
More ▼
Find Funds and ETFs
Find Funds and ETFs
Use our fund screener to discover other asset types.
 
Funds ScreenerGo to the Funds Screener

Asset allocation

Distribution

Type% Net assets% Short% Long
US stock88.48%0.00%88.48%
Non-US stock8.62%0.00%8.62%
Cash1.19%0.07%1.26%
US bond0.00%0.00%0.00%
Non-US bond0.00%0.00%0.00%
Other1.71%0.00%1.71%
As of Sep 30 2024

Weightings

Sectors
Equity
Fixed income
Sector% Net assetsCategory average
Healthcare95.52%97.76%
Other0.00%2.07%
Real Estate0.00%0.10%
Industrials0.00%0.04%
Consumer Defensive0.00%0.03%
As of Sep 30 2024. Sectors weighting is calculated using only long position holdings of the portfolio.

Top 10 holdings

Top 10 holdings as a per cent of portfolio
45.46%57.89%0.00%57.89%
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
AbbVie Inc
ABBV:NYQ		+21.29%18.66%
Amgen Inc
AMGN:NSQ		+8.49%8.79%
Regeneron Pharmaceuticals Inc
REGN:NSQ		-7.27%6.57%
Alnylam Pharmaceuticals Inc
ALNY:NSQ		+50.54%5.05%
Vertex Pharmaceuticals Inc
VRTX:NSQ		+26.45%4.26%
argenx SE
ARGX:NSQ		+20.95%3.55%
Ascendis Pharma A/S
ASND:NSQ		+32.66%3.45%
Vaxcyte Inc
PCVX:NSQ		+67.20%3.09%
Viking Therapeutics Inc
VKTX:NAQ		+337.81%2.41%
Nuvalent Inc
NUVL:NSQ		+51.09%2.06%
Per cent of portfolio in top 10 holdings: 57.89%
Data delayed at least 15 minutes, as of Nov 21 2024.
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2024
All Rights reserved
www.morningstar.com
© 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.